Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

Eli Lilly said it has captured more than 30% of new U.S. patients in oral obesity treatments, narrowing Novo Nordisk's previously estimated 90% share for its Wegovy pill. The oral GLP-1 category could materially expand the obesity-drug market, which analysts project will exceed $100 billion annually in the U.S. by 2030. Lilly also said 60%-70% of patients in Medicare's $50-per-month obesity-drug pilot are new users, while lower-cost generic competition in India and Canada has expanded total Mounjaro volumes despite pressure on share.

Analysis

The relevant read-through is not simply share transfer: a meaningful oral franchise for LLY reduces the probability that NVO retains a scarcity premium in the fastest-growing administration format. If LLY can sustain even a one-third new-start share, the oral category is likely to become a two-player promotional market earlier than consensus models assume, raising selling expense and lowering long-run net-price assumptions for both firms. NVO is more exposed because its valuation still requires strong persistence in obesity leadership, while LLY has a broader earnings base and can use its injectable installed base to lower patient-acquisition costs.

The government-channel mix is a nearer-term volume catalyst for LLY, but investor focus should be on persistence rather than enrollment: a low out-of-pocket program can create a large initial fill rate without proving adherence beyond 3-6 months. The key earnings sensitivity over the next 1-3 quarters is realized net price and discontinuation, not prescription starts. Higher penetration among treatment-naive patients expands the addressable market, but also increases the risk of adverse-event-driven attrition and payer utilization controls once pilot spending becomes visible.

Outside the U.S., low-cost copies create a structural ceiling on branded GLP-1 pricing rather than a clean demand tailwind. LLY may preserve unit growth through category expansion, but international revenue growth can lag volume materially if patients trade down; this is more consequential over 6-18 months as generic availability broadens. Contrarian view: the market may be overreacting to early oral-share snapshots, since channel inventory, formulary positioning and free-trial activity can distort new-patient data; confirmation requires refill and paid-prescription data.

Key Decisions for Investors

• Maintain a 1-3 month relative long LLY / short NVO pair, sized beta-neutral. Catalyst is successive U.S. prescription and formulary data showing durable oral share; target 10-15% relative return. Exit if NVO reclaims greater than 75% of paid oral new starts for two consecutive monthly datasets or if LLY guides to materially higher obesity commercial spend.
• Do not add outright LLY on initial pilot enrollment headlines. Add only after quarterly disclosure supports stable net price and refill persistence; a deceleration in obesity revenue or a step-up in gross-to-net deductions would invalidate the near-term operating-leverage thesis.
• For 6-18 months, monitor LLY international diabetes/obesity revenue growth against unit volumes in Canada and India. If volume rises while reported revenue materially lags, reduce exposure to branded GLP-1 manufacturers and consider a defensive long position in broad healthcare ETF XLV versus LLY/NVO-specific risk.
• Watch Medicare pilot utilization and any CMS budget commentary over the next 1-3 months. Evidence of prior authorization tightening or unexpectedly high discontinuation would be a catalyst to take profits on LLY and reassess category demand assumptions.